COVID-19

The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Clinical News

The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy

Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage clinical trial published yesterday in The Lancet international medical journal.…
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
أخبار

TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed

A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
TIF News (AR)

Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide
TIF News (AR)

Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation
TIF News (AR)

COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation

In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…
Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo
Member News

Joint ETA, TIF & ESHR Conference On Thalassaemia To Take Place On 25-26 November 2020 in Cairo

A Joint Conference on thalassaemia by the Egyptian Thalassemia Association (ETA), the Egyptian Society of Hematology & Research (ESHR) and the Thalassaemia International Federation (TIF) will be held on 25-26…
Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest
أخبار

Pfizer’s COVID-19 Vaccine Candidate Shown To Be 90% Effective, Early Findings Suggest

The drug maker Pfizer announced yesterday that an early analysis of its coronavirus vaccine trial suggested the vaccine was robustly effective in preventing Covid-19, a promising development as the world…
Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19
Clinical News

Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19

The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19. According to Roche, AT-527 blocks the viral RNA polymerase enzyme…
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Clinical News

Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness

Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
زر الذهاب إلى الأعلى